Magic Mushroom Dose Didn't Cure Alzheimer's. It Did Start a Conversation.

She hadn't strung a sentence together in five years. Then, 19 hours after taking a high dose of psilocybin mushrooms, she woke up at 3:30 in the morning and talked for four hours.

A case report published in Frontiers in Neuroscience by researchers at Associação Cruz de Ankh in São Paulo documents what happened to an 80-year-old Japanese-American woman with a decade-long Alzheimer's diagnosis. For the preceding five years, her verbal output had been largely monosyllabic. She was incontinent, had impaired mobility, required help with nearly every activity of daily living, and showed markedly flat affect. Researchers administered a single 5 g oral dose of psilocybin-containing mushrooms (Enigma strain). The acute phase was not gentle: clinically suspected hyperthermia, profuse sweating, and a prolonged deep sleep-like state that reportedly alarmed her caregivers. Then she woke up and started telling stories.

Over the days and weeks that followed, gains accumulated across multiple domains. She regained urinary continence after more than five years. She began walking independently, dressing herself, sustaining eye contact, recognizing family members, asking where people had gone. A second session one month later, at 3 g, was associated with even greater expressiveness, spontaneous humor and, reportedly, improved gait agility.

The authors are careful with their language, and you should be too when reading this: causality cannot be established from a single case report with no neuroimaging, no standardized cognitive scales and no polysomnographic monitoring. Spontaneous fluctuations in neurodegeneration are real. What the researchers suggest is narrower and more interesting than a cure: that residual functional capacity may persist in advanced Alzheimer's, and that psilocybin may transiently make it accessible by reorganizing large-scale brain networks rather than reversing pathology.

Dead neurons don't come back. But a damaged network that can still respond to disruption is a different problem entirely.

Read the full story at IFLScience, June 9, 2026

Hot Take: Late-stage Alzheimer's has been characterized as a hardware failure for decades. What if at least some of it is a software problem? A Brazilian case report with no budget and a 5 g dose of magic mushrooms took that question seriously.